such as nonalcoholic fatty liver disease and hepatitis B, and its main manifestation is the excessive deposition of extracellular matrix in hepatocytes [1, 2]. Hepatic fibrosis mainly occurs due to the activation and proliferation of hepatic stellate cells under the regulation of cytokines secreted by Kupffer cells, which enhances the synthesis of extracellular matrix and reduces its degradation, thus gradually leading to fibrosis formation [3, 4]. Fibrosis can be effectively reversed if drug intervention is administered on time during the occurrence/progression of hepatic fibrosis [5, 6]. During this process, Kupffer cells are activated by external stimuli to secrete cytokines, and they further activate hepatic stellate cells via paracrine effect. Following this, the activated hepatic stellate cells can recruit a large number of Kupffer cells through similar paracrine effects. This cycle is maintained for a long period and continuously promotes hepatic fibrosis [7–9]. Many studies have proved that inflammatory factors and reactive oxygen species play important roles in the aforementioned positive feedback cycle. Therefore, if drugs can improve the functions of the NF-κB and Nrf2 pathways, they can produce some therapeutic effects against hepatic fibrosis [10, 11]. extensa Ginns, Rheum rhabarbarum, Glycyrrhiza uralensis, and synthetic musk. Basic research has shown that the aforementioned components show some antifibrotic effects [12, 13]. As a fixed compound preparation, Biejiaxiaozheng pills have been used in clinical practice for many years, and these pills have been confirmed to be effective in the treatment of hepatic fibrosis through clinical and experimental studies [14, 15]. In the present study, a rat model of hepatic fibrosis was established via carbon tetrachloride (CCl4) induction to study whether Biejiaxiaozheng pills can reverse hepatic fibrosis by improving the functions of the NF-κB and Nrf2 pathways. Biejiaxiaozheng pills (3.6 g/pill) and propranolol (10 mg/pill) were purchased from Zhaoqing Hospital of Traditional Chinese Medicine. Sprague Dawley rats and a high-fat diet were purchased from the Laboratory Animals Center of Hubei Disease Prevention and Control Center (China). CCl4 and TBST with Tween 20 (powder) were purchased from Shanghai Macklin Biochemical Co., Ltd. (Cat. No. C805332, T854550, China). PVDF membrane was purchased from Millipore Inc. (Cat. No. IPVH00010, USA). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) detection kits, total protein detection kit, albumin detection kit, and total bilirubin detection kit were purchased from Nanjing Jiancheng Bioengineering Institute (Cat. No. C010-2-1, C009-2-1, A045-2-2, A028-2-1, C019-1-1, China). TNF-α, IL-1β, and IL-6 ELISA kits were purchased from Dakewe Biotech Co., Ltd. (Cat. No. 1317202, 1310122, 1310602, China). Total RNA rapid extraction kit was purchased from Beijing Tianmo Biotech Co., Ltd. (Cat. No. TR205, China). Total SOD activity detection kit, lipid peroxidation (MDA) detection kit, total glutathione (GSH) detection kit, glutathione peroxidase (GPx) detection kit, SYBR Green qPCR Mix (High ROX), cDNA synthesis reagent kit, DEPC water, BCA protein concentration detection kit, western and IP cellular lysis buffer, protease inhibitor cocktail, SDS-PAGE protein loading buffer, SDS-PAGE gel rapid preparation kit, electrophoresis buffer, transfer buffer, PVDF membrane activation buffer, prestained protein molecular weight standards, dry BSA powder, and ultrasensitive ECL chemiluminescence detection kit were purchased from Beyotime Institute of Biotechnology (Cat. No. S0101, S0131, S0052, S0056, D7265, D7170, R0022, P0010, P0013, P1006, P0286, P0012AC, P0562, P0575, P0021S, P0077, ST023, P0018AS, China). The primary antibodies against p65, P-p65, Nrf2, HO-1, and β-actin as well as HRP-labeled goat anti-rabbit IgG secondary antibodies were purchased from Affinity Biosciences Co. Ltd. (Cat. No. AF5006, AF2006, AF0639, AF5393, AF7018, S0001, USA). 2.2. Establishment of Hepatic Fibrosis Rat Model and Treatment A CCl4/olive oil solution (50% ()) was administered intragastrically twice a week (Monday and Thursday) at 0.2 mL/100 g body weight, combined with high-fat and high-ethanol diets for induction. Distilled